Study of subcutaneous ianalumab in patients with primary Sjögren's syndrome met primary objective, showing dose-related decrease in disease activity (ESSDAI) at week 24: randomised, double-blind, placebo-controlled trial. https://t.co/NqdDWqpX2g https://t.co/PSxSRx28fM